MedX Announces Application for Extension for a further $300,000 of Series I Loan Notes

MedX Announces Application for Extension for a further $300,000 of Series I Loan Notes

Bill Mitoulas, Investor Relations
MedX Health Corp.
bill@medxhealth.com
+1-416-479-9547
or
Stephen Lockyer, President
+1-905-670-4428

In its Press Release dated October 22, 2024, MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced that it had obtained final TSXV Acceptance for extension of the Maturity Date of $2,650,000 out of $3,700,000 of then outstanding Convertible Loan Notes (“Series I Notes”) from December 31, 2023 to December 31, 2025 (the “Extension”), and that it may submit request(s) to the TSXV for Acceptance in the event that additional holders of Series I Notes agreed to accept the Extension. The Company is now pleased to announce that holders of a further $300,000 of Series I Notes have agreed to the Extension, and accordingly the Company has made application to the TSXV for Acceptance, issuance of which is subject to all applicable TSXV Policies.

The Series I Loan Notes, originally issued in the First Quarter of 2021, pay Interest quarterly at 6% per year, originally matured on December 31, 2023 (“Original Maturity Date”) which, where holders have agreed and TSXV Acceptance has been issued, has been extended to December 31, 2025 (“New Maturity Date”), and are convertible, at the option of the holder, into units (“Unit(s)”) at $0.14 per Unit. Each Unit comprises one fully paid common share and one-half of a share purchase warrant (“Warrant(s)”; each whole Warrant is exercisable up until the New Maturity Date to acquire a further common share at $0.20. Subject to, and conditional on Acceptance by the TSXV, the Company will extend maturity date of the further $300,000 of Series I Notes, and the corresponding expiration date of the underlying Warrants, to December 31, 2025.

About MedX Health Corp.:

MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the U.S., Australia, New Zealand, the European Union, Brazil and Turkey. Visit https://medxhealth.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties.